Corporate Banner
Satellite Banner
Technology Networks Header
Wednesday, November 26, 2014
Technology Networks
 
Register | Sign in
Home Page>Posters

  Posters

Enabling Epigenetics Studies from HTS to SAR : A Novel HTRF® Platform to Identify and Characterize Reader Domain Inhibitors
T. Roux1, M. Badol1, N. Douayry1, L. Sergeant1, E.Trinquet1, F. Degorce1, S. Milhas2, S. Betzi2, C. Derviaux2, C. Eydoux3, J. Letienne2, A. Lugari2, Y. Collette2, J-C. Guillemot3 et X. Morelli2

Discover a novel HTRF platform to identify and characterize the vast variety of epigenetic binding domain.

High Throughput Screening in the European Lead Factory
S.P. van Helden, W.H. Rutjes, C.A.A. van Boeckel and J.H.M. van den Broek

This paper describes workflows that have been implemented at the screening centre of the European Lead Factory and presents screening statistics on the first 18 months of operation.

Novel Gpr39 Agonists: Correlation Of Binding Affinity Using Label-Free Back-Scattering Interferometry With Potency In Functional Assays
Daniel Brown (1), Niklas Larsson (2), Ola Fjellström (3), Anders Johansson (3), Sara Lundqvist (2), Johan Brengdahl (2), and Richard J. Isaacs (1)

We describe the application of back-scattering interferometry (BSI) to the characterization of small molecule ligand binding to human GPR39 (a GPCR targeted for type-2 diabetes therapy) overexpressed in crude membrane fractions in free solution, including how BSI-derived affinity and functional assay-derived potency correlate for compounds of varying scaffolds.

Mixtures Analysis of Complex Mixtures
Michael Bernstein; Carlos Cobas; Santi Domínguez; Manuel Pérez; Agustín Barba

We describe an NMR method to quantify mixture components in wine, edible oils, etc. The method is fully customizable, and amenable to high throughput operation.

Novel Gpr39 Agonists: Correlation Of Binding Affinity Using Label-Free Back-Scattering Interferometry With Potency In Functional Assays
Daniel Brown (1), Niklas Larsson (2), Ola Fjellström (3), Anders Johansson (3), Sara Lundqvist (2), Johan Brengdahl (2), and Richard J. Isaacs (1)

We describe the application of back-scattering interferometry (BSI) to the characterization of small molecule ligand binding to human GPR39 (a GPCR targeted for type-2 diabetes therapy) overexpressed in crude membrane fractions in free solution, including how BSI-derived affinity and functional assay-derived potency correlate for compounds of varying scaffolds

GC-MS/MS ANALYSIS OF BENZODIAZEPINES USING ANALYTE PROTECTANTS
Jeremy Matthews, Alex Chen, Flavio Bedini

Purpose: Assess the feasibility of using analyte protectants to improve the analysis of benzodiazepines.

Targeted cancer therapy based on blocking the expression of genes and small doses of oxaliplatin.
Bavykin A.S.1, Korotaeva A.A.1, Poyarkov S.V.2, Syrtsev A.V.1, Karpukhin A.V.1

The major drawbacks of the prescribed chemotherapy, are still remain the significant side effects and drug - resistance. Even targeted chemotherapy by means of specific antibodies do not always help to solve these complications. Our purpose was to identify potential biological targets associated with the development of drug resistance and to develop a specific method of suppressing the viability of cancer cells exposed to low doses of standard chemotherapy.

Inverted Y Approach to Lumbosacral region - Analysis of 525 cases over 10 years
Dr Krishna Kumar and Dr Renjith Kumar

Traditional approach to lumosacral region utilizes midline incision, which often requires long incision to get sufficient exposure. We describe our experience with inverted Y approach to lumbosacral junction.

LC/MS/MS Quantitation of Eicosapentaenoic Acid in Rat Plasma
Rachel Sun, Jordan Nally, Tim Shoaf

Eicosapentaenoic acid (EPA) is an omega-3 fatty acid, which has been documented to be important in biochemical and physiological processes including inflammatory response, blood clotting and the immune system. Eicosapentaenoic acid (EPA) appears in different forms in the blood including triglyceride, ethyl ester, or free acid. In this work we presented an LC/MS/MS method to quantitate the total eicosapentaenoic acid in rat plasma with a 96-well plate format.

Comparison of Dissociated Phoria Measuring Methods. Repeatability and Reliability
Ane Murueta-Goyena Larrañaga

The aim of this study is to determine the reliability and compare reproducibility of different dissociated phoria measure tests.

<< 1 2 3 4 5 >>
Showing Results 1 - 10 of 44
Scientific News
Themis Bioscience’s Vaccine Against Chikungunya Successful in Phase 1
Results presented at international conferences in Philadelphia and New Orleans.
Anti-Leukemia Drug May Also Work Against Ovarian Cancer
An antibody therapy already in clinical trials to treat chronic lymphocytic leukemia (CLL) may also prove effective against ovarian cancer – and likely other cancers as well.
Novel Cancer Vaccine Approach for Brain Tumors
Researchers unravel the mechanisms behind a novel cancer vaccine for brain tumors, paving the way for further development.
Almac Announces Launch of CLIA Validated Next Generation Sequencing Assay
P53 considered important biomarker for cancer drug discovery.
Classification of Gene Mutations in Neuroblastoma
Penn Medicine and CHOP experts define riskier mutations in neuroblastoma, setting stage for clinical trial.
New Vaccine Generates Strong Immune Response Against Hepatitis C
A new hepatitis C vaccine has shown promising results in an early clinical trial at Oxford University, generating strong and broad immune responses against the virus causing the disease.
Immune Booster Helps Improve Survival In Metastatic Melanoma
Patients with metastatic melanoma who were treated with ipilimumab, an immune checkpoint blocker, survived 50 percent longer – a median 17.5 months vs. 12.7 months – if they simultaneously received an immune stimulant.
Protecting us from Our Cells
Growth factor boosts natural defence against auto-immune disorders.
TxCell Achieves Positive Results for Col-Treg in a Model of Autoimmune Uveitis
TxCell set for phase I/II proof of principle clinical study in Q2 2015 for its second therapeutic candidate in this rare eye disease.
NIH Begins Early Human Clinical Trial of VSV Ebola Vaccine
Human testing of a second investigational Ebola vaccine candidate is under way at the National Institutes of Health’s Clinical Center in Bethesda, Maryland.
Scroll Up
Scroll Down
SELECTBIO
SELECTBIO Market Reports
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv